Prevalence of diseases and pathological conditions in young people under 45 years of age with abdominal obesity in Siberia

Aim. To study the prevalence of abdominal obesity in young people aged 25–44 years in Novosibirsk, as well as the prevalence of diseases and pathological conditions in individuals with abdominal obesity.

Materials and methods. We conducted a cross-sectional, population-based study of the population of Novosibirsk aged 25–44 years. The screening examined 1,415 people, including 670 men and 745 women. For all individuals, we evaluated the presence of such conditions as abdominal obesity (AO), arterial hypertension (AH), increased body mass index (BMI), coronary heart disease (according to validated epidemiologic and functional criteria with ECG findings classified according to the Minnesota Code), diabetes mellitus (DM), reduced glomerular filtration rate (GFR), chronic bronchitis (CB), increased blood levels of total cholesterol (hypercholesterolemia) and lowdensity lipoprotein (LDL) cholesterol (hyper-LDL-cholesterolemia).

Results. The prevalence of AO in the population of Novosibirsk aged 25–44 years was 42.4%: in men – 42.7%, in women – 42.1%. We found that AO had a significant direct effect on the development of AH (odds ratio (OR) = 2.550, 95% confidence interval (CI) 1.899–3.422, p = 0.0001), CB (OR = 1.830, CI 1.326–2.527, p = 0.0001), hypercholesterolemia (OR = 1.486, CI 1.193–1.851, p = 0.0001), hyper-LDL-cholesterolemia (OR = 1.527, CI 1.222–1.907, p = 0.0001) and a reverse effect on reduced GFR (OR = 0.603, CI 0.427–0.852, p = 0.004). In the male population under 45 years of age, AO had a significant direct effect on the development of AH, CB, hypercholesterolemia, and hyper-LDL-cholesterolemia. In the female population under the age of 45, AO had a significant direct effect on the development of DM, AH, CB, and hyper-LDL-cholesterolemia and a reverse effect on the reduced GFR development.

Conclusion. Therefore, in the young Siberian population under 45 years of age, abdominal obesity is associated with the development of common diseases and pathological conditions. 

1. Ural D., Kiliçkap M., Göksülük H., Karaaslan D., Kayikçioǧlu M., Özer N., Barçin C., Yilmaz M.B., Abaci A., Şengül Ş., Arinsoy T., Erdem Y., Sanisoǧlu Y., Şahin M., Tokgözoǧlu L. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars. 2018; 46: 577–590. DOI: 10.5543/tkda.2018.62200.

2. Triggiani A.I., Valenzano A., Trimigno V., Di Palma A., Moscatelli F., Cibelli G., Messina G. Heart rate variability reduction is related to a high amount of visceral adiposity in healthy young women. PLoS One. 2019; 14 (2019). DOI: 10.1371/journal.pone.0223058.

3. Kim H.Y., Kim J.K., Shin G.G., Han J.A., Kim J.W. Association between Abdominal Obesity and Cardiovascular Risk Factors in Adults with Normal Body Mass Index: Based on the Sixth Korea National Health and Nutrition Examination Survey. J. Obes. Metab. Syndr. 2019; 28: 262–270. DOI: 10.7570/jomes.2019.28.4.262.

4. Melin E.O., Thulesius H.O., Hillman M., Landin-Olsson M., Thunander M. Abdominal obesity in type 1 diabetes associated with gender, cardiovascular risk factors and complications, and difficulties achieving treatment targets: A cross sectional study at a secondary care diabetes clinic. BMC Obes. 2018; 5. DOI: 10.1186/s40608-018-0193-5.

5. Mohammadi H., Ohm J., Discacciati A., Sundstrom J., Hambraeus K., Jernberg T., Svensson P. Abdominal obesity and the risk of recurrent atherosclerotic cardiovascular disease after myocardial infarction. Eur. J. Prev. Cardiol. 2020; 27: 1944– 1952. DOI: 10.1177/2047487319898019.

6. Alexopoulos N., Katritsis D., Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014; 233: 104–112. DOI: 10.1016/j.atherosclerosis.2013.12.023.

7. Ragino Y.I., Stakhneva E.M., Polonskaya Y.V., Kashtanova E.V. The role of secretory activity molecules of visceral adipocytes in abdominal obesity in the development of cardiovascular disease: A review. Biomolecules. 2020; 10. DOI: 10.3390/biom10030374.

8. Dutheil F., Gordon, B.A. Naughton G., Crendal E., Courteix D., Chaplais E., Thivel D., Lac G., Benson A.C. Cardiovascular risk of adipokines: a review. J. Int. Med. Res. 2018; 46: 2082– 2095. DOI: 10.1177/0300060517706578.

9. Neeland I.J., Ross R., Després J.P., Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos R.D., Arsenault B., Cuevas A., Hu F.B., Griffin B., Zambon A., Barter P., Fruchart J.C., Eckel R.H. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7: 715–725. DOI: 0.1016/S2213-8587(19)30084-1.

10. Vikhireva O., Paja̧ k A., Broda G., Malyutina S., Tamosiunas A., Kubinova R., Simonova G., Skodova Z., Bobak M., Pikhart H. SCORE performance in central and eastern Europe and former Soviet Union: MONICA and HAPIEE results. Eur. Heart J. 2014; 35. DOI: 10.1093/eurheartj/eht189.

11. Alberti K.G.M.M., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P.T., Loria C.M., Smith S.C. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009; 120: 1640–1645. DOI: 10.1161/CIRCULATIONAHA.109.192644.

12. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O., Mueller C., Drexel H., Aboyans V., Corsini A., Doehner W., Farnier M., Gigante B., Kayikcioglu M., Krstacic G., Lambrinou E., Lewis B.S., Masip J., Moulin P., Petersen S., Petronio A.S., Piepoli M.F., Pinto X., Raber L., Ray K.K., Reiner Z., Riesen W.F., Roffi M., Schmid J.P., Shlyakhto E., Simpson I.A., Stroes E., Sudano I., Tselepis A.D., Viigimaa M., Vindis C., Vonbank A., Vrablik M., Vrsalovic M., Gomez J.L.Z., Collet J.P., Windecker S., Dean V., Fitzsimons D., Gale C.P., Grobbee D.E., Halvorsen S., Hindricks G., Iung B., Jüni P., Katus H.A., Leclercq C., Lettino M., Merkely B., Sousa-Uva M., Touyz R.M., Nibouche D., Zelveian P.H., Siostrzonek P., Najafov R., Van De Borne P., Pojskic B., Postadzhiyan A., Kypris L., Spinar J., Larsen M.L., Eldin H.S., Strandberg T.E., Ferrières J., Agladze R., Laufs U., Rallidis L., Bajnok L., Gudjonsson T., Maher V., Henkin Y., Gulizia M.M., Mussagaliyeva A., Bajraktari G., Kerimkulova A., Latkovskis G., Hamoui O., Slapikas R., Visser L., Dingli P., Ivanov V., Boskovic A., Nazzi M., Visseren F., Mitevska I., Retterstøl K., Jankowski P., Fontes-Carvalho R., Gaita D., Ezhov M., Foscoli M., Giga V., Pella D., Fras Z., De Isla L.P., Hagström E., Lehmann R., Abid L., Ozdogan O., Mitchenko O., Patel R.S. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020; 41: 111–188. DOI: 10.1093/eurheartj/ehz455.

13. Alberti K.G.M.M., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Original articles. 1997. DOI: 10.1002/(SICI)1096-9136(199807)15:7.

14. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014; 85: 49–61. DOI: 10.1038/ki.2013.444.

15. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. Population. Am. J. Respir. Crit. Care Med. 1999; 159: 179–187. DOI: 10.1164/ajrccm.159.1.9712108.

16. Sun H., Liu Y., Liu D., Zhou Q., Guo C., Li Q., Tian G., Wu X., Hu D., Sun X., Zhang M. Metabolically healthy general and abdominal obesity are associated with increased risk of hypertension. Br. J. Nutr. 2020; 123: 583–591. DOI: 10.1017/S0007114519003143.

17. Almeida J.B., Kian K.O., Lima R.C., De Souza M.C.C. Total and abdominal adiposity and hypertension in indigenous women in midwest Brazil. PLoS One. 2016; 11: 1–12. DOI: 10.1371/journal.pone.0155528.

18. Pekkarinen E., Vanninen E., Länsimies E., Kokkarinen J., Timonen K.L. Relation between body composition, abdominal obesity, and lung function. Clin. Physiol. Funct. Imaging. 2012; 32: 83–88. DOI: 10.1111/j.1475-097X.2011.01064.x.

19. Vatrella A., Calabrese C., Mattiello A., Panico C., Costigliola A., Chiodini P., Panico S. Abdominal adiposity is an early marker of pulmonary function impairment: Findings from a Mediterranean Italian female cohort. Nutr. Metab. Cardiovasc. Dis. 2016; 26: 643–648. DOI: 10.1016/j.numecd.2015.12.013.

20. Borges M.D., Franca E.L., Fujimori M., Silva S.M.C., de Marchi P.G.F., Deluque A.L., Honorio-Franca A.C., de Abreu L.C. Relationship between proinflammatory cytokines/chemokines and adipokines in serum of young adults with obesity, endocrine, metab. immune disord. Drug Targets. 2018; 18: 260–267. DOI: 10.2174/1871530318666180131094733.

21. Hertelyova Z., Salaj R., Chmelarova A., Dombrovsky P., Dvorakova M.C., Kruzliak P. The association between lipid parameters and obesity in university students. J. Endocrinol. Invest. 2016; 39: 769–778. DOI: 10.1007/s40618-015-0240-8.

22. Salehinia F., Abdi H., Hadaegh F., Serahati S., Valizadeh M., Azizi F., Hosseinpanah F. Abdominal obesity phenotypes and incident diabetes over 12 years of follow-up: The Tehran Lipid and glucose study. Diabetes Res. Clin. Pract. 2018; 144: 17–24. DOI: 10.1016/j.diabres.2018.07.021.

23. Sarathy H., Henriquez G., Abramowitz M.K., Kramer H., Rosas S.E., Johns T., Kumar J., Skversky A., Kaskel F., Melamed M.L. Abdominal obesity, race and chronic kidney disease in young adults: Results from NHANES 1999–2010. PLoS One. 2016; 11. DOI: 10.1371/journal.pone.0153588.

24. Dias R.S.C., Calado I.L., De Alencar J.D., Hortegal E.V., Santos E.J.F., De Araújo Brito D.J., Lages J.S., Dos Santos A.M., Filho N.S. Abdominal obesity and reduction of glomerular filtration. Rev. Assoc. Med. Bras. 2018; 64: 346–353. DOI: 10.1590/1806-9282.64.04.346.

25. Tsao Y.C., Chen J.Y., Yeh W.C., Li W.C. Gender- and age-specific associations between visceral obesity and renal function impairment. Obes. Facts. 2019; 12: 67–77. DOI: 10.1159/000496626.

26. Shahali A., Tasdighi E., Barzin M., Mahdavi M., Valizadeh M., Niroomand M., Azizi F., Hosseinpanah F. Abdominal obesity phenotypes and risk of kidney function decline: Tehran Lipid and Glucose Study. Obes. Res. Clin. Pract. 2020; (14): 168– 175. DOI: 10.1016/j.orcp.2020.03.006.